Provided by Tiger Trade Technology Pte. Ltd.

Ashland

53.61
+2.805.51%
Post-market: 53.610.00000.00%16:04 EDT
Volume:815.24K
Turnover:43.23M
Market Cap:2.45B
PE:-3.54
High:53.75
Open:51.57
Low:51.15
Close:50.81
52wk High:65.65
52wk Low:45.21
Shares:45.76M
Float Shares:41.77M
Volume Ratio:1.07
T/O Rate:1.95%
Dividend:1.65
Dividend Rate:3.08%
EPS(TTM):-15.1257
EPS(LYR):-18.3696
ROE:-29.98%
ROA:2.09%
PB:1.31
PE(LYR):-2.92

Loading ...

Ashland Inc. Awards CEO Guillermo Novo $2 Million One-Time Equity Grant

Reuters
·
Jan 28

Ashland, Univar Solutions announce exclusive distribution partnership

TIPRANKS
·
Jan 27

Earning Preview: Ashland—Revenue Seen Soft This Quarter; Institutional Views Tilt Cautiously Positive

Earnings Agent
·
Jan 26

Ashland Shareholders Approve Directors, Auditor and Executive Pay

TIPRANKS
·
Jan 23

Ashland Inc. Held Annual Shareholder Meeting

Reuters
·
Jan 23

Ashland Inc. schedules first-quarter earnings release and webcast

Reuters
·
Jan 21

Press Release: Ashland board authorizes quarterly dividend

Dow Jones
·
Jan 20

How Strengthening Analyst Consensus On Specialty Focus At Ashland (ASH) Has Changed Its Investment Story

Simply Wall St.
·
Jan 15

Press Release: Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

Dow Jones
·
Jan 14

Ashland Is Maintained at Buy by Argus Research

Dow Jones
·
Jan 13

UBS Adjusts Price Target on Ashland to $70 From $64, Maintains Buy Rating

MT Newswires Live
·
Jan 12

Ashland price target raised to $70 from $64 at UBS

TIPRANKS
·
Jan 12

Ashland price target raised to $70 from $65 at Argus

TIPRANKS
·
Jan 12

Press Release: Rigel Provides Business Update and 2026 Outlook

Dow Jones
·
Jan 12

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

GlobeNewswire
·
Jan 12

Ashland Inc : Argus Research Raises Target Price to $70 From $65

THOMSON REUTERS
·
Jan 12

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 12

Cellectis Announces 2026 Strategy and Catalysts

GlobeNewswire
·
Jan 09

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

GlobeNewswire
·
Jan 08

Major IPO Update: Former CICC Research MD Leads Suzhou InnovaBio's Rapid Listing Acceptance on STAR Market

Deep News
·
Dec 24, 2025